Pharma e Biotech - Europa NicOx : Quelli che aspettano ,,,, ridendo !!! (1 Viewer)
- Creatore Discussione acqua+
- Data di Inizio
- Stato
coxy
coxy
vediamo di proporci una digressione sul tema osteoarthritis.
dolore, infiammazione, danno biologico etc etc.
Fermo restando che il goal long term e far ricostruire i tessuti articolari (dieci anni),
al momento oltre ad un antinfiammatorio ci serve anche un analgesico, e forse anche un delivery system nuovo.
Pfizer e' nel capitale Nicox, e' nel capitale di Psivida, ha accordi con B&L e con Adolor.
Se non erro con Adolor inizia una fase III per l'osteoartrite (non ho capito quale forma).
Ovviamente qualcuno e' certamente piu' bravo ad esaminare gli accordi ed i dettagli, pero' come strategia generale sommministrare il naproxcinod ed un pain reliever di nuova generazione mi intriga. Soprattutto se viene portato avanti come programma negli ospedali, e non nelle farmacie.
dolore, infiammazione, danno biologico etc etc.
Fermo restando che il goal long term e far ricostruire i tessuti articolari (dieci anni),
al momento oltre ad un antinfiammatorio ci serve anche un analgesico, e forse anche un delivery system nuovo.
Pfizer e' nel capitale Nicox, e' nel capitale di Psivida, ha accordi con B&L e con Adolor.
Se non erro con Adolor inizia una fase III per l'osteoartrite (non ho capito quale forma).
Ovviamente qualcuno e' certamente piu' bravo ad esaminare gli accordi ed i dettagli, pero' come strategia generale sommministrare il naproxcinod ed un pain reliever di nuova generazione mi intriga. Soprattutto se viene portato avanti come programma negli ospedali, e non nelle farmacie.
coxy
coxy
Si incentiva l'inutile (elettrodomestici, nautica, fotovoltaico, auto), ma quale vantaggio avrebbe invece un piano di salute pubblica che migliora le capacita' produttive e di lavoro della popolazione oltre i 60 anni? un tre-4 giorni di lavoro in piu' all'anno quanto fanno per lo Stato?
ovviamente e' un modo di pensare fuori dalla realta'....
ovviamente e' un modo di pensare fuori dalla realta'....
doctor NO
NO nel DNA
coxy
coxy
Da seeking alpha del 3 marzo 2010........I do see continued growth with ENTEREG, but I also believe the company’s greatest story may yet to be told. Its partnership with Pfizer Inc. (PFE)in the development of a new class of opioids --- the delta receptor opioid. This class of opioid analgesics would work effectively in pain management without offering numerous complicating side effects that the traditional opioids retain such as sedation, respiratory depression and abuse potential.
Management has reported progress in a Phase 3 trial involving the compounds AVL5859 and AVL5747 in osteoarthritis patients. The trial will enroll 400 patients and compare each compound against placebo and oxycodone CR. The study will last two weeks and results are expected at the end of this year.
ecco il punto di partenza..mo' comincia lo studio...che .alle.
Management has reported progress in a Phase 3 trial involving the compounds AVL5859 and AVL5747 in osteoarthritis patients. The trial will enroll 400 patients and compare each compound against placebo and oxycodone CR. The study will last two weeks and results are expected at the end of this year.
ecco il punto di partenza..mo' comincia lo studio...che .alle.
doctor NO
NO nel DNA
e-Abstract: 1274-351 Topic: Vascular Biology/Atherosclerosis/Thrombosis/Endothelium Authors: Manlio Bolla, Alessandra Poggi, Barbara Vergani, Guido Gelpi, Julio Padron, Daniela Miglietta, NicOx Research, Milan, Italy, NicOx SA, Sophia Antipolis, France
Enlarge
Enlarge
Enlarge
http://files.abstractsonline.com/CTRL/02/d/c68/d1e/944/4fe/69a/e56/b27/a57/78f/9d/a13705_1.jpg
Enlarge
Enlarge
http://files.abstractsonline.com/CTRL/02/d/c68/d1e/944/4fe/69a/e56/b27/a57/78f/9d/a13705_2.gif
Enlarge
http://files.abstractsonline.com/CTRL/02/d/c68/d1e/944/4fe/69a/e56/b27/a57/78f/9d/a13705_3.gif
Enlarge
http://files.abstractsonline.com/CTRL/02/d/c68/d1e/944/4fe/69a/e56/b27/a57/78f/9d/a13705_4.gif
Enlarge
Enlarge
Background
Hypertension is a frequent co-morbidity in patients with osteoarthritis (OA) (Singh et al, 2002). Non steroidal anti-inflammatory drugs (NSAIDs) are the mainstay treatment of OA; however, their long term use may increase blood pressure, likely by inhibiting cyclooxygenase (COX)-derived prostanoids in the vascular bed (Antman et al, 2007). Endothelium-derived vasodil...Read More »
Methods
Human internal mammary artery (hIMA) specimens from patients undergoing coronary artery bypass grafting (CABG) were prepared as rings and mounted for the measurement of isometric tone. Response of KCl-precontracted rings to acetylcholine (ACh, 10 mM) or sodium nitroprusside (SNP, 1 mM) was assessed. After wash-out, KCl-precontracted arteries were exposed to naproxcinod or naproxen...Read More »
Results
In pre-contracted hIMA, endothelium-dependent vasorelaxation (acetylcholine) was reduced in comparison to the endothelium-independent (sodium nitroprusside) response. Accordingly, electron microscopy showed cellular abnormalities such as intima hyperplasia and endothelial cell degeneration. Naproxcinod (10 nM - 100 mM) caused a NO-mediated concentration-dependent relaxation (Emax= -52.4±6.9%,...Read More »
Conclusions
Cyclooxygenase inhibition in arteries with endothelial dysfunction results in vasoconstriction, suggesting an important role of COX-derived prostaglandins (likely from COX-2) in the regulation and maintenance of vascular tone. Nitric oxide donation from naproxcinod suppresses the vasoconstricting effect due to COX inhibition. In cardiovascular diseases accompanied by en...Read More »
Disclosures
M Bolla, A Poggi, J Padron and D Miglietta are current NicOx employees. B Vergani received research support from NicOx. Read More »
coxy che ne pensi della presentazione??????????
coxy
coxy
Che accordo strano....da monitorare
Pfizer Collaboration
(dal sito Adolor)
In December 2007, we announced an exclusive, world-wide collaboration with Pfizer, Inc. to develop and commercialize our Delta compounds. The agreement focuses on ADL5859 and ADL5747 for pain indications but also has the potential to encompass other product candidates and therapeutic applications. Adolor will be responsible for IND filings and clinical evaluation through Phase 2a, at which point Pfizer will undertake the completion of development, regulatory approval and commercialization for each compound. Adolor will share profits with Pfizer in the United States and receive royalties on net sales outside the country.
adesso andiamoci a vedere i recettori e le molecole. two months...e poi dicono
Pfizer Collaboration
(dal sito Adolor)
In December 2007, we announced an exclusive, world-wide collaboration with Pfizer, Inc. to develop and commercialize our Delta compounds. The agreement focuses on ADL5859 and ADL5747 for pain indications but also has the potential to encompass other product candidates and therapeutic applications. Adolor will be responsible for IND filings and clinical evaluation through Phase 2a, at which point Pfizer will undertake the completion of development, regulatory approval and commercialization for each compound. Adolor will share profits with Pfizer in the United States and receive royalties on net sales outside the country.
adesso andiamoci a vedere i recettori e le molecole. two months...e poi dicono
magolibero
..se la sà gira..
magolibero
..se la sà gira..
- Stato